DS 1501

Drug Profile

DS 1501

Alternative Names: Anti-siglec-15-antibody-Daiichi-Sankyo; DS-1501a; DS1501; Siglec-15 Ab

Latest Information Update: 24 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Daiichi Sankyo Company
  • Class Antibodies; Osteoporosis therapies
  • Mechanism of Action Siglec-15 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Osteoporosis

Most Recent Events

  • 23 Jan 2018 3297334 - Updated KDM and scientific section (PD). HE already present
  • 08 Sep 2017 Phase-I clinical trials in Osteoporosis (In volunteers) in Japan (SC) (Before September 2017)
  • 08 Sep 2017 Pharmacokinetics and adverse events data from a phase l trial in Osteoporosis presented at the 39th Annual Meeting of the American Society for Bone and Mineral Research (ASBMR-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top